13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorBritish Columbia Cancer Agency
About this trial
The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients. This observational study involves intravenous infusion of \[U-13C\]glucose into patients during standard paracentesis.
Eligibility criteria
Qualifiers
Ovarian cancer
Any stage or grade of disease
Ascites fluid that requires draining
Any treatment regimen
Disqualifiers
Participants must not have diabetes or abnormal hemoglobin A1C levels.
The patient's glucose levels must be between 4 - 11.1 mM before administering an infusion. This is to ensure that patients are within normal blood glucose levels, as described by Diabetes Canada.
Participants cannot receive chemotherapy treatment during the 5 hour duration of the experiment as it may compromise the integrity of the data.
Trial design
Treatments tested in this trial
- [U-13C]Glucose
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
British Columbia Cancer Agency
Lead sponsor
University of Texas Southwestern Medical Center
Collaborator
Van Andel Research Institute
Collaborator
University of Victoria
Collaborator
Source ClinicalTrials.gov